Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Neovascular AMD”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Ended earlyNCT05571267
What this trial is testing

Safety Study of Zimura in Combination With Anti-VEGF Therapy in Patients With Neovascular AMD

Who this might be right for
Neovascular Age-Related Macular Degeneration
IVERIC bio, Inc. 1
Large-scale testing (Phase 3)Active Not RecruitingNCT04704921
What this trial is testing

Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD

Who this might be right for
AMDnAMDWet Age-related Macular Degeneration+6 more
AbbVie 671
Not applicableNot Yet RecruitingNCT07581782
What this trial is testing

Prospective, Single Arm, Observational Study of Faricimab in the Treatment of Neovascular Age-related Macular Degeneration (nAMD)

Who this might be right for
Neovascular Age-related Macular Degeneration(nAMD)
Sun Yat-sen University 50
Not applicableUnknownNCT05220085
What this trial is testing

Beovu Experience UZ Leuven

Who this might be right for
Age-Related Macular Degeneration
Universitaire Ziekenhuizen KU Leuven 17
Testing effectiveness (Phase 2)Study completedNCT03022318
What this trial is testing

Carbidopa-levodopa in Neovascular AMD

Who this might be right for
Age-related Macular Degeneration
Snyder, Robert W., M.D., Ph.D., P.C. 20
Testing effectiveness (Phase 2)Looking for participantsNCT06492863
What this trial is testing

Gene Therapy(FT-003) for Wet AMD

Who this might be right for
Neovascular Age-related Macular Degeneration
Frontera Therapeutics 78
Not applicableStudy completedNCT04455399
What this trial is testing

Time Efficiency Comparison of Two IntraVitreal Injection Techniques

Who this might be right for
Neovascular Age-related Macular DegenerationDiabetic Macular EdemaRetinal Vein Occlusion With Macular Edema+2 more
Peregrine Eye and Laser Institute 200
Not applicableStudy completedNCT05131646
What this trial is testing

Extension Study to Evaluate the Long-term Outcomes of Subjects in the CLS-AX CLS1002-101 Study

Who this might be right for
Neovascular Age-related Macular Degeneration
Clearside Biomedical, Inc. 15
Large-scale testing (Phase 3)Study completedNCT00967213
What this trial is testing

Combination of Ranibizumab and Verteporfin Therapy in Neovascular Age-related Macular Degeneration

Who this might be right for
Neovascular Age-related Macular Degeneration
Novartis Korea Ltd. 10
Large-scale testing (Phase 3)WithdrawnNCT00390026
What this trial is testing

The Avastin vs Visudyne for Neovascular AMD Study

Who this might be right for
Age-related Macular Degeneration
St. Erik Eye Hospital
Testing effectiveness (Phase 2)Study completedNCT01674569
What this trial is testing

Pilot Study of X-82 in Patients With Wet AMD

Who this might be right for
Exudative Macular Degeneration
Tyrogenex 35
Not applicableStudy completedNCT02173496
What this trial is testing

Colour Contrast Sensitivity for the Early Detection of Wet Age-related Macular Degereration (CEDAR)

Who this might be right for
Age Related Macular Degeneration
Aston University 233
Not applicableStudy completedNCT01773954
What this trial is testing

Repeated Eye Injections of Aflibercept for Treatment of Wet Age Related Macular Degeneration

Who this might be right for
Age-Related Macular DegenerationMacular Degeneration
MidAtlantic Retina 40
Not applicableStudy completedNCT03909425
What this trial is testing

Defining Disease Activity in Neovascular AMD With Optical Coherence Tomography Angiography

Who this might be right for
Neovascular Age-related Macular Degeneration
Moorfields Eye Hospital NHS Foundation Trust 35
Early research (Phase 1)Study completedNCT03249740
What this trial is testing

A Depot Formulation of Sunitinib Malate (GB-102) in Subjects With Neovascular (Wet) Age-related Macular Degeneration

Who this might be right for
Neovascular Age-Related Macular Degeneration
Graybug Vision 32
Early research (Phase 1)Study completedNCT01255462
What this trial is testing

Intravitreal LFG316 in Patients With Advanced Age-related Macular Degeneration

Who this might be right for
Advanced Age-related Macular Degeneration
Novartis Pharmaceuticals 24
Not applicableStudy completedNCT06231121
What this trial is testing

Switching to Faricimab in Neovascular Age-related Macular Degeneration Resistant to Both Aflibercept and Ranibizumab

Who this might be right for
Neovascular Age-related Macular Degeneration
Rigshospitalet, Denmark 13
Not applicableStudy completedNCT05146687
What this trial is testing

Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Age-related Macular Degeneration (AMD) Who Received Anti-vascular Endothelial Growth Factor (VEGF) Agents (Komodo Health)

Who this might be right for
Age-related Macular Degeneration (AMD)
Novartis Pharmaceuticals 369,600
Testing effectiveness (Phase 2)Study completedNCT00376701
What this trial is testing

Combination Therapy for Age-Related Macular Degeneration.

Who this might be right for
Age Related Macular Degeneration
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's 103
Large-scale testing (Phase 3)Not Yet RecruitingNCT07816289
What this trial is testing

Phase 3 Study of Intravitreal OLN324 in Adults With Neovascular (Wet) Age-related Macular Degeneration (nAMD) (OLN324-CP-05)

Who this might be right for
Wet Age-related Macular Degeneration
Ollin Biosciences, Inc. 400
Next Page